Skip to content
Biodatica
Start free

EMD Serono Research & Development Institute, Inc.

Fort Lauderdale, Florida

OncologyPhase IIListed · MKKGY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

yesterdayTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

90no change

Momentum 90 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Oct 10, 2025

    Advanced Solid Tumor · RECRUITING · sponsor: EMD Serono Research & Development Institute, Inc. · M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

    ClinicalTrials.gov · NCT07166601 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Oct 4, 2022

    Cancer · RECRUITING · sponsor: EMD Serono Research & Development Institute, Inc. · Met Non Small Cell Cancer Registry (MOMENT)

    ClinicalTrials.gov · NCT05376891 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Aug 17, 2022

    Locally Advanced or Metastatic Urothelial Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: EMD Serono Research & Development Institute, Inc. · A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

    ClinicalTrials.gov · NCT05327530 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources